Moses Makunje
Vermogen: 325 695 $ op 31-05-2026
Vermogen: 325 695 $ op 31-05-2026
Moses Makunje is currently VP-Finance & Principal Accounting Officer at Nuvation Bio, Inc. since 2020.
Formerly, Mr. Makunje was Controller at Adverum Biotechnologies, Inc. from 2017 to 2019 and Controller at Maze Therapeutics, Inc. from 2019 to 2020.
Mr. Makunje completed undergraduate and MBA degrees at Golden Gate University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 27-02-2026 | 68.137 ( 0,02% ) | 325 695 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| NUVATION BIO INC. | Comptroller/Controller/Auditor | 27-11-2023 |
| Bedrijven | Functie | Einde |
|---|---|---|
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases | Comptroller/Controller/Auditor | 01-07-2020 |
| ADVERUM BIOTECHNOLOGIES, INC. | Comptroller/Controller/Auditor | 01-03-2019 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Golden Gate University
Golden Gate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells novel gene therapies | Health Technology |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases | Health Technology |
Nuvation Bio, Inc.
Nuvation Bio, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops oncology related novel therapeutic candidates | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau